Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Samlowski W, Robert NJ, Nwokeji ED, Baidoo B, Schenkel B, Moshyk A, Kotapati S, Poretta T, Weber JS. Abstract 1043: Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks vs other dosing regimens as treatment for melanoma in the adjuvant setting. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

For:	Samlowski W, Robert NJ, Nwokeji ED, Baidoo B, Schenkel B, Moshyk A, Kotapati S, Poretta T, Weber JS. Abstract 1043: Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks vs other dosing regimens as treatment for melanoma in the adjuvant setting. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

Number

Cited by Other Article(s)

Takamoto K, Komori T, Ishida Y, Kambe N, Kabashima K. Up-dosing of nivolumab may induce serious immune-related adverse events. J Eur Acad Dermatol Venereol 2021;36:e141-e142. [PMID: 34551172 DOI: 10.1111/jdv.17701] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 09/16/2021] [Indexed: 12/18/2022]